Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

OBJECTIVES: To determine the activity and tolerability of 100-mg once-daily (QD) dasatinib in patients with metastatic castration-resistance prostate cancer (CRPC). Dasatinib, an oral Src family kinase inhibitor, has demonstrated both preclinical and clinical activity with twice-daily dosing in pati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yu, Evan Y., Massard, Christophe, Gross, Mitchell E., Carducci, Michael A., Culine, Stephane, Hudes, Gary, Posadas, Edwin M., Sternberg, Cora N., Wilding, George, Trudel, Géralyn C., Paliwal, Prashni, Fizazi, Karim
Formato: Artigo
Lenguaje:Inglês
Publicado: 2011
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394099/
https://ncbi.nlm.nih.gov/pubmed/21539969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urology.2011.01.006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares